Wird geladen...
Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Lymphoproliferative Disorders
INTRODUCTION: Chemoimmunotherapeutic regimens using the anti-CD20 antibody rituximab improved significantly the survival rates in various B-cell lymphoproliferative disorders (LPDs), including chronic lymphocytic leukemia (CLL). The next-generation CD20 antibody obinutuzumab represents an addition t...
Gespeichert in:
| Veröffentlicht in: | Expert Opin Biol Ther |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166403/ https://ncbi.nlm.nih.gov/pubmed/28893099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1377178 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|